L-Theanine and Mood: What the 2026 Meta-Analysis of 31 Trials Found
A new systematic review and meta-analysis in Molecular Psychiatry pools 31 randomised trials of L-theanine. Here is what it found on attention, stress, and depressive symptoms, and where the evidence is still thin.
Research context: This article discusses a peer-reviewed systematic review and meta-analysis and the primary trials it draws on. It is intended for informational and educational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before making changes to diet, lifestyle, or supplementation.
A pooled answer to a question that has run for two decades
L-theanine has been sold as a calming, focus-supporting amino acid for so long that it is easy to forget how thin the underlying trial base actually is. Individual studies have been small, used different doses, different outcome measures, and different populations, which makes it hard to know whether the compound has a real, replicable effect or whether the reputation outran the data.
A new systematic review and meta-analysis published in Molecular Psychiatry in July 2026 by Cyril Gerolymos, Elisa Saddier, Laurent Boyer, and Guillaume Fond, all based at Aix-Marseille University and Assistance Publique-Hopitaux de Marseille, pools 31 randomised controlled trials of oral L-theanine against placebo across 1,168 participants in both healthy and clinical populations. It is the largest quantitative synthesis of L-theanine trial data published to date, and it gives a more precise (and more mixed) answer than the supplement-marketing version of the story usually allows.
What the meta-analysis actually measured
The authors set a single pre-specified primary outcome: the acute effect of a single dose on stress in healthy adults. Everything else was treated as secondary, which matters, because it is the secondary findings that turned out to be the most interesting part of the paper. Secondary outcomes included stress after repeated dosing, anxiety, depressive symptoms, and fatigue on the clinical side, plus reaction time and attention-task performance after single and repeated doses on the cognitive side. The team also compared dropout rates and reasons for dropout between L-theanine and placebo arms as a safety check.
The results, outcome by outcome
Attention and reaction time. The clearest signal in the whole dataset. A single 200 mg dose taken 30 to 60 minutes before cognitive testing significantly improved choice reaction time, with a standardised mean difference of 0.51 (95% CI 0.25 to 0.77). That is a moderate effect size by conventional benchmarks, and it held up as the most consistent finding across the pooled trials.
Acute stress. The primary outcome came back weaker than the attention result. The reduction in acute stress after a single dose was modest, SMD 0.31, and the authors flagged that the effect was largely driven by studies carrying a high risk of bias. Strip those out and the stress-reduction case gets noticeably thinner.
Fatigue. No significant effect was observed. This is worth sitting with, since fatigue reduction is one of the effects most commonly implied in consumer marketing.
Depressive symptoms. After excluding one statistical outlier, the pooled trials showed a significant reduction in depressive symptoms following a single dose in healthy individuals, SMD 0.69 (95% CI 0.13 to 1.25), with low heterogeneity between studies. This is the finding the authors themselves describe as warranting confirmation rather than as settled, but a moderate-to-large effect size with low heterogeneity in a pooled analysis is not a trivial result.
Anxiety. Inconsistent and largely non-significant, with one exception: a single trial in patients with psychotic anxiety showed a significant effect (SMD 0.54) at 400 mg per day over eight weeks. One positive trial in a specific clinical population is a signal to investigate further, not evidence that L-theanine treats anxiety broadly.
Safety. No serious adverse events were reported across the pooled trials, and dropout patterns did not differ meaningfully between L-theanine and placebo arms.
The authors' own framing is appropriately restrained: L-theanine is safe and shows a robust short-term benefit on attention in healthy adults, with a potential antidepressant effect that warrants confirmation in high-quality trials, particularly in clinical populations. That is a considerably more careful statement than "reduces stress and fatigue," which is roughly the claim most retail listings make.
Why the older evidence pointed a different direction
Before this meta-analysis, the case for L-theanine rested heavily on mechanism and on a handful of small trials, several of which are now folded into the pooled dataset. Two are worth knowing individually because they shaped the compound's reputation.
The EEG work by Nobre, Rao, and Owen, published in the Asia Pacific Journal of Clinical Nutrition in 2008, showed that a single 50 mg dose of L-theanine increased alpha-band brain activity relative to placebo in healthy participants at rest, with the effect replicated in a second cohort engaged in a passive task. Alpha activity is associated with a relaxed but alert mental state rather than drowsiness, and this study is the usual citation behind the "calm focus" framing of L-theanine. It is a real, replicated electrophysiological finding, but it is a proxy measure, not a clinical or cognitive-performance endpoint on its own.
A separate randomised, placebo-controlled, crossover trial by Hidese and colleagues, published in Nutrients in 2019, gave 30 healthy adults 200 mg per day of L-theanine or placebo for four weeks. Depression-scale, trait-anxiety, and Pittsburgh Sleep Quality Index scores all improved significantly on L-theanine relative to placebo, along with verbal fluency and executive-function scores on cognitive testing. It is a small trial (n=30) and a single study, but its outcome pattern (mood and sleep improvements alongside modest cognitive gains) previews almost exactly what the 2026 meta-analysis found at a much larger scale: a real attention effect, and a mood effect that is promising but needs more data behind it.
How this fits with the caffeine pairing
Most people encounter L-theanine as the second half of the caffeine and L-theanine combination rather than as a standalone compound. That pairing has its own, more extensively replicated evidence base for attention and sustained focus, covered in our caffeine and L-theanine synergy guide. The 2026 meta-analysis is useful context for that combination too: the attention benefit it confirms for L-theanine alone is consistent with, and probably contributes to, the combination's reputation for smoothing out caffeine's edge without blunting alertness. The GABA and alpha-wave mechanisms underlying L-theanine's calming profile are discussed in more depth in our GABA pathway nootropics review.
Dose and timing signal from the pooled data
The strongest and most consistent effect in the meta-analysis, on attention, came from a single 200 mg dose taken 30 to 60 minutes before the cognitive task. That figure lines up with the dose used in most of the individual trials feeding the pooled analysis, including Hidese's 200 mg per day protocol. The anxiety signal that did reach significance used a considerably higher dose (400 mg per day) sustained over eight weeks in a clinical population, which is a different use case entirely and not something the healthy-adult attention data can be extrapolated to.
What is still missing
The authors are explicit that the antidepressant signal needs confirmation in high-quality trials, particularly in clinical populations rather than healthy volunteers. The acute stress-reduction result loses most of its weight once high-risk-of-bias studies are removed, which is a meaningful caveat for a compound often marketed primarily as a stress reliever. The anxiety data is too inconsistent across 31 trials to support a general claim, positive or negative. And nearly all of the dataset covers single-dose or short repeated-dose windows measured in weeks, not months, so long-term use patterns remain largely uncharacterised by controlled trial data.
Key takeaways
A meta-analysis of 31 randomised trials and 1,168 participants gives L-theanine its most solid evidence yet for one specific effect: improved attention and choice reaction time after a single 200 mg dose. The depressive-symptom finding is promising and statistically clean but explicitly flagged by the authors as needing replication. The acute stress-reduction and fatigue claims, the ones most often used in marketing, come out weaker than the attention finding once bias is accounted for. Anxiety effects remain inconsistent outside one specific clinical trial. None of this changes L-theanine's excellent safety profile, but it does narrow the honest claim down from "reduces stress and improves mood" to "reliably supports attention, with a mood signal worth watching."
FAQ
Does this meta-analysis prove L-theanine reduces anxiety?
No. Anxiety outcomes across the 31 pooled trials were inconsistent and mostly non-significant. The one significant anxiety result came from a single trial in patients with psychotic anxiety at 400 mg per day for eight weeks, a specific clinical context that does not generalise to healthy adults taking L-theanine for everyday anxiety.
Is the attention benefit real or just a marketing claim?
The attention finding is the strongest result in the entire analysis: a moderate effect size (SMD 0.51) on choice reaction time after a single 200 mg dose, consistent across the pooled trials. Of all the claims commonly made about L-theanine, this is the one with the best current trial support.
Should I take L-theanine for depression based on this study?
The pooled data shows a statistically significant reduction in depressive symptoms after a single dose in healthy individuals, but the authors describe this as needing confirmation in high-quality trials, especially in people with diagnosed depression rather than healthy volunteers. It is a genuinely interesting signal, not a demonstrated treatment effect. Anyone with clinical depression should discuss treatment options with a healthcare provider rather than substituting a supplement.
What dose did the strongest results in the meta-analysis use?
The attention benefit was strongest with a single 200 mg dose taken 30 to 60 minutes before cognitive testing, matching the dose used in most of the individual trials in the pooled dataset, including the earlier Hidese trial. The one positive anxiety result used a higher, sustained dose of 400 mg per day for eight weeks in a clinical population, a different protocol entirely.
Primary sources: Gerolymos C, Saddier E, Boyer L, Fond G. "Cognitive and affective effects of L-Theanine: a systematic review and meta-analysis of 31 randomized trials." Molecular Psychiatry 2026. DOI: 10.1038/s41380-026-03727-9. PMID: 42410082. Hidese S, Ogawa S, Ota M, et al. "Effects of L-Theanine Administration on Stress-Related Symptoms and Cognitive Functions in Healthy Adults: A Randomized Controlled Trial." Nutrients 2019;11(10):2362. DOI: 10.3390/nu11102362. PMID: 31623400. Nobre AC, Rao A, Owen GN. "L-theanine, a natural constituent in tea, and its effect on mental state." Asia Pacific Journal of Clinical Nutrition 2008;17 Suppl 1:167-168. PMID: 18296328. This article summarises published trial data and is not a substitute for individualised medical advice.
Disclaimer
This article is for educational and research-context purposes only. It does not constitute medical advice and is not a substitute for consultation with a qualified healthcare practitioner. The trials and meta-analysis discussed reflect published research findings, not personalised clinical guidance. Always consult a doctor before beginning, modifying, or stopping any supplement, particularly if you have a diagnosed mental health condition, are pregnant or breastfeeding, or take prescription medications.